140 related articles for article (PubMed ID: 17387455)
1. Differential role of epigenetic modulators in malignant and normal stem cells: a novel tool in preclinical in vitro toxicology and clinical therapy.
Snykers S; Vinken M; Rogiers V; Vanhaecke T
Arch Toxicol; 2007 Aug; 81(8):533-44. PubMed ID: 17387455
[TBL] [Abstract][Full Text] [Related]
2. Epigenetic drugs as pleiotropic agents in cancer treatment: biomolecular aspects and clinical applications.
Sigalotti L; Fratta E; Coral S; Cortini E; Covre A; Nicolay HJ; Anzalone L; Pezzani L; Di Giacomo AM; Fonsatti E; Colizzi F; Altomonte M; Calabrò L; Maio M
J Cell Physiol; 2007 Aug; 212(2):330-44. PubMed ID: 17458893
[TBL] [Abstract][Full Text] [Related]
3. Histone deacetylase inhibitors as a new weapon in the arsenal of differentiation therapies of cancer.
Botrugno OA; Santoro F; Minucci S
Cancer Lett; 2009 Aug; 280(2):134-44. PubMed ID: 19345000
[TBL] [Abstract][Full Text] [Related]
4. Epigenetic tools in potential anticancer therapy.
Sebova K; Fridrichova I
Anticancer Drugs; 2010 Jul; 21(6):565-77. PubMed ID: 20436342
[TBL] [Abstract][Full Text] [Related]
5. Epi-drugs to fight cancer: from chemistry to cancer treatment, the road ahead.
Mai A; Altucci L
Int J Biochem Cell Biol; 2009 Jan; 41(1):199-213. PubMed ID: 18790076
[TBL] [Abstract][Full Text] [Related]
6. Epigenetics and the plasticity of differentiation in normal and cancer stem cells.
Lotem J; Sachs L
Oncogene; 2006 Dec; 25(59):7663-72. PubMed ID: 16847453
[TBL] [Abstract][Full Text] [Related]
7. Targeting epigenetic abnormalities with histone deacetylase inhibitors.
Conley BA; Wright JJ; Kummar S
Cancer; 2006 Aug; 107(4):832-40. PubMed ID: 16826577
[TBL] [Abstract][Full Text] [Related]
8. Novel approaches on epigenetics.
Papait R; Monti E; Bonapace IM
Curr Opin Drug Discov Devel; 2009 Mar; 12(2):264-75. PubMed ID: 19333872
[TBL] [Abstract][Full Text] [Related]
9. Epigenetic therapy in cancer: molecular background and clinical development of histone deacetylase and DNA methyltransferase inhibitors.
Schneider-Stock R; Ocker M
IDrugs; 2007 Aug; 10(8):557-61. PubMed ID: 17665331
[TBL] [Abstract][Full Text] [Related]
10. Development of vorinostat: current applications and future perspectives for cancer therapy.
Richon VM; Garcia-Vargas J; Hardwick JS
Cancer Lett; 2009 Aug; 280(2):201-10. PubMed ID: 19181442
[TBL] [Abstract][Full Text] [Related]
11. Histone deacetylase inhibitors: apoptotic effects and clinical implications (Review).
Emanuele S; Lauricella M; Tesoriere G
Int J Oncol; 2008 Oct; 33(4):637-46. PubMed ID: 18813776
[TBL] [Abstract][Full Text] [Related]
12. Histone deacetylase inhibitors for epigenetic therapy of cancer.
Monneret C
Anticancer Drugs; 2007 Apr; 18(4):363-70. PubMed ID: 17351388
[TBL] [Abstract][Full Text] [Related]
13. Epigenetic alterations and cancer: new targets for therapy.
Allen A
IDrugs; 2007 Oct; 10(10):709-12. PubMed ID: 17899489
[TBL] [Abstract][Full Text] [Related]
14. Epigenetic changes in cancer as potential targets for prophylaxis and maintenance therapy.
Grønbaek K; Treppendahl M; Asmar F; Guldberg P
Basic Clin Pharmacol Toxicol; 2008 Nov; 103(5):389-96. PubMed ID: 18947362
[TBL] [Abstract][Full Text] [Related]
15. Deciphering the underlying genetic and epigenetic events leading to gastric carcinogenesis.
Vogiatzi P; Vindigni C; Roviello F; Renieri A; Giordano A
J Cell Physiol; 2007 May; 211(2):287-95. PubMed ID: 17238139
[TBL] [Abstract][Full Text] [Related]
16. Histone acetylation and chromatin signature in stem cell identity and cancer.
Shukla V; Vaissière T; Herceg Z
Mutat Res; 2008 Jan; 637(1-2):1-15. PubMed ID: 17850830
[TBL] [Abstract][Full Text] [Related]
17. Acute myeloid leukemia: therapeutic impact of epigenetic drugs.
Altucci L; Clarke N; Nebbioso A; Scognamiglio A; Gronemeyer H
Int J Biochem Cell Biol; 2005 Sep; 37(9):1752-62. PubMed ID: 15964234
[TBL] [Abstract][Full Text] [Related]
18. HDAC inhibitors: clinical update and mechanism-based potential.
Glaser KB
Biochem Pharmacol; 2007 Sep; 74(5):659-71. PubMed ID: 17498667
[TBL] [Abstract][Full Text] [Related]
19. Concise review: roles of polycomb group proteins in development and disease: a stem cell perspective.
Rajasekhar VK; Begemann M
Stem Cells; 2007 Oct; 25(10):2498-510. PubMed ID: 17600113
[TBL] [Abstract][Full Text] [Related]
20. Epigenetic therapy using the histone deacetylase inhibitor for increasing therapeutic gain in oral cancer: prevention of radiation-induced oral mucositis and inhibition of chemical-induced oral carcinogenesis.
Chung YL; Lee MY; Pui NN
Carcinogenesis; 2009 Aug; 30(8):1387-97. PubMed ID: 19351790
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
